期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

口服抗凝药华法林的药物基因组学研究进展 被引量：3

Progress in the pharmacogenomics of the oral anticoagulant agent warfarin
下载PDF
导出
摘要 华法林是一个治疗范围窄、剂量个体差异大的口服抗凝药物,决定其维持剂量的有遗传和某些非遗传因素,其中编码代谢酶和维生素K环氧化物降解酶的基因变异是研究最广泛的遗传因素。本文对华法林的药物基因学的部分研究内容进行了综述,以便临床更好开展个体化治疗,减少出血等不良反应。 The oral anticoagulant warfarin has a narrow therapeutic range and wide inter- individual dosing requirements, genetic factors together with several non - genetic patient - specific factors are important determi- nants of stable dose requirement for the agent. Genotype for CYP2C9 and vitamin K epoxide reductase complex subunit （ 1 - VKORC1 ） , which en- codes the main functional variants of genes affecting warfarin metabolism and activity, were widely investigated. We reviewed some literatures a- bout pharmacogenomics of warfarin, that may help clinicians to give indi- vidualized therapy on patients, and minimize adverse drug reaction such as bleeding.
作者 季闽春 沈晓英 徐琳 杨耀芳
机构地区 复旦大学附属上海市第五人民医院药剂科
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2010年第9期696-700,共5页 The Chinese Journal of Clinical Pharmacology
关键词 华法林 药物基因组学 抗凝 warfarin pharmacogenomics anticoagulant
分类号 R973.2 [医药卫生—药品] R968 [医药卫生—药理学]
  • 相关文献

参考文献1

二级参考文献21

  • 1Aithal GP,Day CP,Keateven PJ,Daly AK.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet 1999; 353:717-719.
  • 2Higashi MK,Veenstra DL,Kondo LM,Wittkowsky AK,Srinouanprachanh SL,Farin FM,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA 2002; 287:1690-1698.
  • 3Taube J,Halsall D,Baglin T.Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation on patients on long-term treatment.Blood 2000; 96:1816-1819.
  • 4Kirchheiner J,Brockmoller J.Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin Pharmacol Ther 2005; 77:1-16.
  • 5Rieder MJ,Reiner AP,Gage BF,Nickerson DA,Eby CS,McLeod HL,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N Engl J Med 2005; 352:2285-2293.
  • 6Montes R,Gaona ER,Martinez-Gonzalez MA,Aoberca I,Hermida J.The c.-1639G >A polymorphism of the VKORC1 gene is a major determinant of the response to acemocoumarol in anticoagulated patients.Br J Haematol.2006; 133:183-187.
  • 7Yuan HY,Chen JJ,Lee MT,Wung JC,Chen YF,Chamg MJ,et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum Mol Genet 2005; 14:1745-1751.
  • 8Wadelius M,Chen LY,Dowries K,Ghori J,Hunt S,Eriksson N,et al.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.Pharmacogenomics J 2005; 5:262-270.
  • 9Bodin L,Verstuyft C,Tregouet DA,Robert A,Dubert L,Funck-Brentano C,et al.Cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood 2005; 106:135-140.
  • 10D'Andrea G,D'Ambtosio RL,Di Perna P,Chetta M,Santacroce R,Brancaccio V,et al.A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.Blood 2005; 105:645-649.

同被引文献19

  • 1张宏礼,张鸿雁.关于最大信息熵原理与群体遗传平衡一致性的探讨[J].遗传,2006,28(3):324-328. 被引量：27
  • 2AithalGP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with Warfarin dose requirement and risk of bleedincomplications.Lancet,1999,353(9154):717-719.
  • 3Lee CR,Goldstein JA,Pieper JA.Cytochmem p450 2C9 palymorphisins:a comprchansive review of the in vitro and human data.Phanacogeneics and Genomics,2002,12(3):251-263.
  • 4Tham LS,Goh BC,Nafziger A,et al.A warfarin-dosing model in Asians that uses single-nucl eotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.Clin Pharmacol Ther,2006,80(4):346-55.
  • 5Takahashi H,Wilkinson GR,Nutescu EA,et al.Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin In Japanese,Caucasians and African-Americans.Pharmacogenet and genomics,2006;16(2):101-110.
  • 6Limdi NA,Arnett DK,Goldstein JA,et al.Influence of CYP2C9 and VKORC1 on warfarin dose,anticoagulation attainment and maintenance among European-Americans and African-Americans.Pharmacogenomics,2008(9):511-526.
  • 7Sconce EA,Khan TI,Wynne HA,et al.The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen.Blood,2005,106:2329-2333.
  • 8Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA:the journal of the American Association,2002,287(13):1690-1698.
  • 9Tham LS,Goh BC,Nafziger A,et al.A Warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 & ast.Clin Pharmacol Ther,2006,80(4):346-355.
  • 10Rieder MJ,Reiner AP,Gage BF,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N Engl J Med,2005,352(22):2285-2293.

引证文献3

二级引证文献2

中国临床药理学杂志
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部